NEWS & EVENTS
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent and Zumutor Biologics Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors
Feb 11, 2020
Catalent today announced that it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors.
Catalent Completes Acquisition of MaSTherCell
Feb 10, 2020
Catalent, Inc. today announced that it had completed its acquisition of MaSTherCell Global Inc., positioning Catalent as a premier technology, development and manufacturing partner for innovators of advanced biotherapeutics.
Catalent To Acquire Leading Cell Therapy Company MaSTherCell Global
Feb 3, 2020
Catalent and MaSTherCell Global, Inc. today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. for an aggregate of $315 million in cash.
Catalent Biologics Supports DiaMedica’s New Treatment for Chronic Kidney Disease
Jan 23, 2020
Catalent today welcomed the news that DiaMedica Therapeutics has received U.S. FDA approval to commence Phase 2 clinical trials of its lead candidate, DM199, for chronic kidney disease.
Catalent to Discuss Ways of Increasing Accuracy and Speed in Assay Development at CASSS WCBP Symposium
Jan 21, 2020
Catalent today announced that Christopher Hepler, Manager, Catalent Biologics Analytical Development, has been invited to speak on ways to improve assay development at the upcoming CASSS WCBP symposium, which will be held on Jan 28 – 30, 2020.
Catalent Further Strengthens Biologics Business with Key Senior Appointments
Jan 16, 2020
Catalent today announced the appointment of Karen Flynn as President of Biologics and Chief Commercial Officer. Ms. Flynn has also joined the company’s Executive Leadership Team and will report to Alessandro Maselli, Catalent’s President and Chief Operating Officer.
Catalent Completes Purchase of Biologics Fill-Finish and Oral Solid Dose Facility in Anagni, Italy
Jan 7, 2020
Catalent today announced the completion of the purchase of Bristol-Myers Squibb’s biologics, sterile, and oral solid dose product manufacturing and packaging facility in Anagni, Italy.
Enhanced Cell Line Productivity Technology to be Introduced by Catalent Biologics at PEGS Europe
Nov 12, 2019
Catalent today announced that Greg Bleck, Ph.D., Global Head of R&D, Catalent Biologics will present at the upcoming annual PEGS Europe conference, which will be held at the Lisboa Congress Center, Lisbon, Portugal, on Nov. 18 – 22, 2019.
Catalent to Discuss the Future of Cell and Gene Therapy Manufacturing at World Orphan Drug Congress Europe
Nov 5, 2019
Catalent today announced it will present at the upcoming World Orphan Drug Congress Europe, being held at Hotel Sofia, Barcelona, Spain on Nov. 12 – 14, 2019.
CASSS WCBP
Date: January 28-30, 2020
Setting Up Your Small Molecules and Biologics for Success
Date: March 5, 2020
Building Stronger Consulting Relationships to Advance Biologic Development Together
Date: March 11, 2020
Achieving Integrated Biologics Development
Date: March 12, 2020
ISBioTech Spring Meeting
Date: March 23-25, 2020
BEBPA Bioassay Conference
Date: March 25-27, 2020
Master Class: How to Accelerate Early Drug Development in Oncology for Small Molecules and Biologics
Date: March 26, 2020
4th Annual Gene Therapy For Rare Disorders Conference
Date: March 30 – April 2, 2020
World Vaccine Congress
Date: April 6-9, 2020
CASSS BIOASSAY
Date: April 26-28, 2020
Interphex
Date: April 28-30, 2020
World Orphan Drug Congress
Date: April 30 – May 1, 2020
PEGS Boston
Date: May 4-8, 2020
ASGCT Annual Meeting
Date: May 12-15, 2020
BEBPA HCP
Date: May 13-15, 2020
ISCT 2020
Date: May 27-30, 2020
BIO International Convention
Date: June 8-11, 2020